Drug Delivery In Breast Cancer Research Articles

PH-responsive magnetic CuFe2O4-PMAA nanogel conjugated with amino-modified lignin for controlled breast cancer drug delivery

In this study, a novel magnetic and pH-responsive nanocarrier was developed, incorporating both natural and synthetic polymers, for delivering curcumin (CUR) to breast cancer cells. For this purpose, CuFe2O4@poly(methacrylic acid) (CuFe2O4@PMAA) nanogel was developed and conjugated with amino-modified lignin (Lignin-adipic acid dihydrazide conjugate, Lig-ADH) to achieve the CuFe2O4@PMAA@Lig-ADH nanocarrier. The morphology, structure, and physical properties of the synthesized nanomaterials were examined using a range of techniques, including transmission electron microscopy (TEM), field emission scanning electron microscopy (FESEM), Fourier transform infrared (FT-IR) spectroscopy, X-ray diffraction (XRD), energy dispersive X-ray (EDX), and vibrating sample magnetometer (VSM). The synthesized nanocarrier exhibited a spherical shape, with an average diameter of approximately 15 nm, and demonstrated good magnetic responsiveness. Moreover, the in vitro drug release was found to be pH-dependent, with an increased release rate in acidic conditions. To evaluate cytotoxicity, the survival of MCF-7 cells was measured using the MTT assay for 24 h. Notably, the synthesized CuFe2O4@PMAA@Lig-ADH@CUR and CUR exhibited significant cytotoxic effects, effectively eliminating MCF-7 cells with IC50 values of 39.80 µg/mL and 4.27 µg/mL, respectively. Also, the significant intracellular uptake of NPs was confirmed by FITC and DAPI staining after 4 h. This research highlighted the potential of CuFe2O4@PMAA@Lig-ADH@CUR as a highly effective nano-delivery system and demonstrated a straightforward method for utilizing renewable lignin.

Folic acid-conjugated bovine serum albumin-coated selenium-ZIF-8 core/shell nanoparticles for dual target-specific drug delivery in breast cancer.

Methotrexate (MTX), a frequently used chemotherapeutic agent, has limited water solubility, leading to rapid clearance even in local injections. In the present study, we developed folic acid-conjugated BSA-stabilized selenium-ZIF-8 core/shell nanoparticles for targeted delivery of MTX to combat breast cancer. FT-IR, XRD, SEM, TEM, and elemental mapping analysis confirmed the successful formation of FA-BSA@MTX@Se@ZIF-8. The developed nano-DDS had a mean diameter, polydispersity index, and zeta potential of 254.8nm, 0.17, and - 16.5 mV, respectively. The release behavior of MTX from the nanocarriers was pH-dependent, where the cumulative release percentage at pH 5.4 was higher than at pH 7.4. BSA significantly improved the blood compatibility of nanoparticles so that after modifying their surface with BSA, the percentage of hemolysis decreased from 12.67 to 5.12%. The loading of methotrexate in BSA@Se@ZIF-8 nanoparticles reduced its IC50 on 4T1 cells from 40.29µg/mL to 16.54µg/mL, and by conjugating folic acid on the surface, this value even decreased to 12.27µg/mL. In vivo evaluation of the inhibitory effect in tumor-bearing mice showed that FA-BSA@MTX@Se@ZIF-8 caused a 2.8-fold reduction in tumor volume compared to the free MTX, which is due to the anticancer effect of selenium nanoparticles, the pH sensitivity of ZIF-8, and the presence of folic acid on the surface as a targeting agent. More importantly, histological studies and animal body weight monitoring confirmed that developed nano-DDS does not have significant organ toxicity. Taking together, the incorporation of chemotherapeutics in folic acid-conjugated BSA-stabilized selenium-ZIF-8 nanoparticles may hold a significant impact in the field of future tumor management.

PH‐responsive bionanocomposite pectin grafted with dimethylaminoethyl methacrylate and acrylic acid copolymer along with silver nanoparticles for breast cancer drug delivery

AbstractIn this study, we developed a pH‐responsive hydrogel membrane composed of pectin, dimethylaminoethyl methacrylate (DMAEMA), and acrylic acid (AA) through a free radical‐triggered graft copolymerization method. Freshly formed silver nanoparticles (AgNPs) produced from the reduction reaction were embedded in the produced hydrogel. Pectin‐grafted dimethylaminoethyl methacrylate and acrylic acid copolymer [poly (DMAEMA‐co‐AA)‐g‐pectin] and its bionanocomposite with AgNPs were confirmed by Fourier‐transform infrared spectroscopy (FT‐IR), scanning electron microscopy (SEM), and thermogravimetric analysis (TGA). The swelling behavior of poly (DMAEMA‐co‐AA)‐g‐pectin in solutions with diverse pH values was assessed. For use as a controlled drug delivery agent, the hydrogel was loaded with 5‐fluorouracil (5‐FU). The incorporation of AgNPs had a great impact on the entrapment efficiency of 5‐FU. At pH 7.4, nearly 48% of the 5‐FU was released in vitro from the polymeric nanocomposite within 24 h. Moreover, poly (DMAEMA‐co‐AA)‐g‐pectin and poly (DMAEMA‐co‐AA)‐g‐pectin/AgNPs presented high cytocompatibility toward normal skin fibroblast cells (BJ1), and the drug delivery system strongly inhibited human Caucasian breast adenocarcinoma cells (MCF‐7). These results demonstrated that these poly (DMAEMA‐co‐AA)‐g‐pectin/AgNPs are an excellent candidate for use in anticancer drug delivery systems.Highlights Free radical polymerization of nanocomposites incorporated with nanoparticles. Nanoparticles improve the bionanocomposites' drug loading. The developed bionanocomposites exhibit control drug release. The novel bionanocomposites acts as an excellent anticancer drug carrier.

WITHDRAWN: Folic acid Grafted, cell-penetrating peptide conjugated pH-sensitive hydrophobically modified Glycol chitosan nanoparticles for drug delivery in breast cancer

Nanocarriers are an outcome of the fast development of nanotechnology; however, delivering drugs to tumor sites effectively is still a major difficulty. A pH-responsive drug carrier with good cell penetration and targeting ability was developed to release the drug exactly to the cancer site and overcome these limitations.The drug carrier FA-TAT-HGCNPs/PTX, which is pH-responsive, uses folic acid (FA) and TAT peptide to deliver paclitaxel (PTX) for target folate-receptor-overexpressing breast cancer cells. 2-(diisopropylamino) ethyl methacrylate was connected to glycol chitosan (GC) to form HGCNPs. Then TAT and HGCNPs were conjugated and FA was grafted onto the HGCNPs’ hydroxyl group. Physicochemical characterizations of FA-TAT-HGCNPs was also evaluated. The maximum DLE and EE values of the FA-TAT-HGCNPs at pH 8.0 were 74.0 ± 2.22 % and 93.7 ± 2.8 %, respectively. FA-TAT-HGCNPs, for instance, showed stability during long-term storage and lyophilization while exhibiting pH-responsive dissociation properties. The synthesized drug carrier was characterized by FTIR, XRD, SEM, HRTEM, DLS, and Zeta analysis. MTT assay exhibited the high anticancer activity of the FA-TAT-HGCNPs/PTX against the MCF-7 cells, whereas drug-free ones are highly biocompatible. The pharmacokinetic results showed twice the bioavailability of FA-TAT-HGCNPs/PTX compared to HGCNPs/PTX. Unlike FA-HGCNPs/PTX, CLSM analysis showed that FA-TAT-HGCNPs/PTX had a significantly more efficient intracellular uptake in MCF-7 cells. These data have shown the transmembrane ability of TATpeptide,the targeting effects of folate decoration, and the synergistic interaction between them.According to these findings, PTX-loaded FA-TAT-HGCNPs offer a potentially effective nanoscale drug delivery system for the treatment of breast cancer.

Niosomes as a Nanocarrier for Breast Cancer Drug Delivery Applications

Niosomes as a Nanocarrier for Breast Cancer Drug Delivery Applications

Advancing Breast Cancer Drug Delivery: The Transformative Potential of Bioinformatics and Artificial Intelligence

Abstract: Breast cancer remains a significant global health challenge, necessitating innovative approaches to improve treatment efficacy while minimizing side effects. This review explores the promising advancements in breast cancer drug delivery driven by the transformative potential of bioinformatics and Artificial Intelligence (AI). Bioinformatics plays a pivotal role in unraveling the intricate genomic landscape of breast cancer, enabling the identification of potential drug targets and biomarkers. The integration of multi-omics data facilitates a comprehensive understanding of the disease, guiding personalized treatment strategies. Moreover, bioinformatics-driven approaches aid in biomarker discovery and prediction, offering novel tools for prognosis and treatment response assessment. AI, particularly machine learning and deep learning, has revolutionized breast cancer research. Machine learning models empower accurate diagnosis through image analysis, improve survival prediction, and enhance risk assessment. Deep learning algorithms, such as convolutional neural networks, enable precise tumor detection and classification from medical imaging data, notably mammograms and MRI scans. Additionally, natural language processing techniques facilitate the mining of vast scientific literature, uncovering hidden insights and identifying potential drug targets. Network-based approaches integrated with AI algorithms facilitate the identification of central proteins as promising drug targets within complex biological networks. This review also examines AIoptimized nanoformulations designed to enhance targeted drug delivery. AI-guided design of drugloaded nanoparticles improves drug encapsulation efficiency, release kinetics, and site-specific delivery, offering promising solutions to overcome the challenges of conventional drug delivery.

Dehydrocurvularin-loaded mPEG-PLGA nanoparticles for targeted breast cancer drug delivery: preparation, characterization, in vitro, and in vivo evaluation

Dehydrocurvularin (DCV) is a promising lead compound for anti-cancer therapy. Unfortunately, the development of DCV-based drugs has been hampered by its poor solubility and bioavailability. Herein, we prepared a DCV-loaded mPEG-PLGA nanoparticles (DCV-NPs) with improved drug properties and therapeutic efficacy. The spherical and discrete particles of DCV-NPs had a uniform diameter of 101.8 ± 0.45 nm and negative zeta potential of −22.5 ± 1.12 mV (pH = 7.4), and its entrapment efficiency (EE) and drug loading (DL) were ∼53.28 ± 1.12 and 10.23 ± 0.30%, respectively. In vitro the release of DCV-NPs lasted for more than 120 h in a sustained-release pattern, its antiproliferation efficacy towards breast cancer cell lines (MCF-7, MDA-MB-231, and 4T1) was better than that of starting drug DCV, and it could be efficiently and rapidly internalised by breast cancer cells. In vivo DCV-NPs were gradually accumulated in tumour areas of mice and significantly suppressed tumour growth. In summary, loading water-insoluble DCV onto nanoparticles has the potential to be an effective agent for breast cancer therapy with injectable property and tumour targeting capacity.

Cutting-edge approaches for targeted drug delivery in breast cancer: beyond conventional therapies.

Breast cancer is a global health challenge with staggering statistics underscoring its pervasive impact. The burden of this disease is measured in terms of its prevalence and the challenges it poses to healthcare systems, necessitating a closer look at its epidemiology and impact. Current breast cancer treatments, including surgery, chemotherapy, radiation therapy, and targeted therapies, have made significant strides in improving patient outcomes. However, they are not without limitations, often leading to adverse effects and the development of drug resistance. This comprehensive review delves into the complex landscape of breast cancer, including its incidence, current treatment modalities, and the inherent limitations of existing therapeutic approaches. It also sheds light on the promising role of nanotechnology, encompassing both inorganic and organic nanoparticles equipped with the ability to selectively deliver therapeutic agents to tumor sites, in the battle against breast cancer. The review also addresses the emerging therapies, their associated challenges, and the future prospects of targeted drug delivery in breast cancer management.

Lipid-based nanoparticle-mediated combination therapy for breast cancer management: a comprehensive review.

Breast cancer due to the unpredictable and complex etiopathology combined with the non-availability of any effective drug treatment has become the major root of concern for oncologists globally. The number of women affected by the said disease state is increasing at an alarming rate attributed to environmental and lifestyle changes indicating at the exploration of a novel treatment strategy that can eradicate this aggressive disease. So far, it is treated by promising nanomedicine monotherapy; however, according to the numerous studies conducted, the inadequacy of these nano monotherapies in terms of elevated toxicity and resistance has been reported. This review, therefore, puts forth a new multimodal strategic approach to lipid-based nanoparticle-mediated combination drug delivery in breast cancer, emphasizing the recent advancements. A basic overview about the combination therapy and its index is firstly given. Then, the various nano-based combinations of chemotherapeutics involving the combination delivery of synthetic and herbal agents are discussed along with their examples. Further, the recent exploration of chemotherapeutics co-delivery with small interfering RNA (siRNA) agents has also been explained herein. Finally, a section providing a brief description of the delivery of chemotherapeutic agents with monoclonal antibodies (mAbs) has been presented. From this review, we aim to provide the researchers with deep insight into the novel and much more effective combinational lipid-based nanoparticle-mediated nanomedicines tailored specifically for breast cancer treatment resulting in synergism, enhanced antitumor efficacy, and low toxic effects, subsequently overcoming the hurdles associated with conventional chemotherapy.

Construction of bionic nanoparticles camouflaged with macrophage membranes for drug delivery in breast cancer

Construction of bionic nanoparticles camouflaged with macrophage membranes for drug delivery in breast cancer

Functionalized liposomes for targeted breast cancer drug delivery.

Despite the exceptional progress in breast cancer pathogenesis, prognosis, diagnosis, and treatment strategies, it remains a prominent cause of female mortality worldwide. Additionally, although chemotherapies are effective, they are associated with critical limitations, most notably their lack of specificity resulting in systemic toxicity and the eventual development of multi-drug resistance (MDR) cancer cells. Liposomes have proven to be an invaluable drug delivery system but of the multitudes of liposomal systems developed every year only a few have been approved for clinical use, none of which employ active targeting. In this review, we summarize the most recent strategies in development for actively targeted liposomal drug delivery systems for surface, transmembrane and internal cell receptors, enzymes, direct cell targeting and dual-targeting of breast cancer and breast cancer-associated cells, e.g., cancer stem cells, cells associated with the tumor microenvironment, etc.

A review of nanomaterials from synthetic and natural molecules for prospective breast cancer nanotherapy.

Breast cancer being one of the most frequent cancers in women accounts for almost a quarter of all cancer cases. Early and late-stage breast cancer outcomes have improved dramatically, with considerable gains in overall survival rate and disease-free state. However, the current therapy of breast cancer suffers from drug resistance leading to relapse and recurrence of the disease. Also, the currently used synthetic and natural agents have bioavailability issues which limit their use. Recently, nanocarriers-assisted delivery of synthetic and natural anticancer drugs has been introduced to the breast cancer therapy which alienates the limitations associated with the current therapy to a great extent. Significant progress has lately been made in the realm of nanotechnology, which proved to be vital in the fight against drug resistance. Nanotechnology has been successfully applied in the effective and improved therapy of different forms of breast cancer including invasive, non-invasive as well as triple negative breast cancer (TNBC), etc. This review presents a comprehensive overview of various nanoformulations prepared for the improved delivery of synthetic and natural anticancer drugs alone or in combination showing better efficacy and pharmacokinetics. In addition to this, various ongoing and completed clinical studies and patents granted on nanotechnology-based breast cancer drug delivery are also reviewed.

Sequential delivery of PD-1/PD-L1 blockade peptide and IDO inhibitor for immunosuppressive microenvironment remodeling via an MMP-2 responsive dual-targeting liposome.

Intelligent responsive drug delivery system opens up new avenues for realizing safer and more effective combination immunotherapy. Herein, a kind of tumor cascade-targeted responsive liposome (NLG919@Lip-pep1) is developed by conjugating polypeptide inhibitor of PD-1 signal pathway (AUNP-12), which is also a targeted peptide that conjugated with liposome carrier through matrix metalloproteinase-2 (MMP-2) cleavable peptide (GPLGVRGD). This targeted liposome is prepared through a mature preparation process, and indoleamine-2,3-dioxygenase (IDO) inhibitor NLG919 was encapsulated into it. Moreover, mediated by the enhanced permeability and retention effect (EPR effect) and AUNP-12, NLG919@Lip-pep1 first targets the cells that highly express PD-L1 in tumor tissues. At the same time, the over-expressed MMP-2 in the tumor site triggers the dissociation of AUNP-12, thus realizing the precise block of PD-1 signal pathway, and restoring the activity of T cells. The exposure of secondary targeting module II VRGDC-NLG919@Lip mediated tumor cells targeting, and further relieved the immunosuppressive microenvironment. Overall, this study offers a potentially appealing paradigm of a high efficiency, low toxicity, and simple intelligent responsive drug delivery system for targeted drug delivery in breast cancer, which can effectively rescue and activate the body's anti-tumor immune response and furthermore achieve effective treatment of metastatic breast cancer.

Dual-targeting exosomes for improved drug delivery in breast cancer.

Aims: Theauthors investigated whether displaying more than one homing peptide enhanced the tumor-targeting efficiency of exosomes. Materials & methods: Exosomes from human embryonic kidney cells (HEK293F) were engineered to display either mono- or dual-tumor-penetrating peptides, iRGD and tLyp1. Exosomes were purified via tangential flow filtration followed by ultracentrifugation. Results: When loaded with doxorubicin (Dox), the dual iRGD-tLyp1 exosomes strongly enhanced Dox uptake in both MCF-7 and MDA-MB-231 breast cancer cell lines, superior to single iRGD or tLyp1 exosomes. The dual iRGD-tLyp1 exosomal Dox was also the most potent, with IC50/GI50 values being 3.7-17.0-times lower than those of free Dox and other exosomal Dox. Conclusion: Selecting appropriate combinatorial homing peptides could be an approach for future precision nanomedicine.

Cytotoxicity of curcumin-loaded magnetic nanoparticles against normal and cancer cells as a breast cancer drug delivery system

Recently, therapeutic applications of modified magnetic nanoparticles have attracted the attention of many researchers. The reason is the ability to develop nano drugs as cancer treatment agents. For this purpose, these particles must have a tiny size, intrinsic magnetic properties, imaging effectiveness, the ability to target the drug, and high drug absorption. Although studies have been performed on the anti-cancer properties of curcumin/nanoparticles, no comprehensive research has been performed to evaluate its anti-cancer and the normal cell toxicity of this drug system for breast cancer treatment. This study designed a curcumin-loaded MNPs (MNPs@CUR) formulation to accomplish these unique features. Using the diffusion process, chemical precipitation was used to make MNPs, which were then loaded with curcumin (CUR). Transmission electron microscopy (TEM) was used to study the morphology and size of MNP-CUR. The fabricated MNPs had spherical shapes with an average length of 23.22 nm. The presence of curcumin on the surface of MNPs was approved using Fourier transform infrared (FTIR) analysis. The X-ray diffraction (XRD) diffractogram confirmed the face cubic center (fcc) character of MNPs. After 24 hours of incubation with 4t1 breast cancer cells, MNPs@CUR anticancer effects were evaluated. MNPs@CUR displayed a concentration-dependent preference for applying anticancer effects on 4t1cells (IC50=108 µg/ml). Separated in vivo anti-tumor studies of coated/naked nanoparticles and curcumin also demonstrated that MNPs@CUR eliminated tumor mass. The cytotoxicity and genotoxicity against normal peripheral blood mononuclear cells (PBMC) were also measured by 2,5-diphenyl-2H-tetrazolium bromide (MTT) electrophoresis DNA digestion methods respectively for MNPs@CUR and naked MNPs. Cytotoxicity was demonstrated at high concentrations of MNP@CUR (991 µg/ml), while naked nanoparticles showed approximately no toxicity and neither had genotoxicity.

Nutraceutical-Based Nanoformulations for Breast and Ovarian Cancer Treatment.

Different strategies have been investigated for a more satisfactory treatment of advanced breast cancer, including the adjuvant use of omega-3 polyunsaturated fatty acids (PUFAs). These nutritional compounds have been shown to possess potent anti-inflammatory and antiangiogenic activities, the capacity to affect transduction pathways/receptors involved in cell growth and to reprogram tumor microenvironment. Omega-3 PUFA-containing nanoformulations designed for drug delivery in breast cancer were shown to potentiate the effects of enclosed drugs, enhance drug delivery to target sites, and minimize drug-induced side effects. We have critically analyzed here the results of the most recent studies investigating the effects of omega-3 PUFA-containing nanoformulations in breast cancer. The anti-neoplastic efficacy of omega-3 PUFAs has also been convincingly demonstrated by using preclinical in vivo models of ovarian cancer. The results obtained are critically analyzed here and seem to provide a sufficient rationale to move to still lacking interventional clinical trials, as well as to evaluate possible advantages of enclosing omega-3 PUFAs to drug-delivery nanosystems for ovarian cancer. Future perspectives in this area are also provided.

Formulation, Optimization, and Evaluation of Moringa oleifera Leaf Polyphenol-Loaded Phytosome Delivery System against Breast Cancer Cell Lines.

Moringa oleifera leaf polyphenols (Mopp) were encapsulated with phytosomes to enhance their efficacy on 4T1 cancer cell lines. The Mopp were extracted via microwave-assisted extraction. Moringa oleifera polyphenol-loaded phytosomes (MoP) were prepared with the nanoprecipitation method and characterized using the dynamic light scattering and dialysis membrane techniques. The in vitro cytotoxic and antiproliferative activity were investigated with the (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazole) MTT assay. Acute toxicity was assessed using Swiss albino mice. An MoP particle size of 296 ± 0.29 nm, −40.1 ± 1.19 mV zeta potential, and polydispersity index of 0.106 ± 0.002 were obtained. The total phenolic content was 50.81 ± 0.02 mg GAE/g, while encapsulation efficiency was 90.32 ± 0.11%. The drug release profiles demonstrated biphasic and prolonged subsequent sustained release. In vitro assays indicated MoP had a low cytotoxicity effect of 98.84 ± 0.53 μg/mL, doxorubicin was 68.35 ± 3.508, and Mopp was 212.9 ± 1.30 μg/mL. Moreover, MoP exhibited the highest antiproliferative effect on 4T1 cancer cells with an inhibitory concentration of 7.73 ± 2.87 μg/mL and selectivity index > 3. The results indicated a significant difference (p ≤ 0.001) in MoP when compared to Mopp and doxorubicin. The in vivo investigation showed the safety of MoP at a dose below 2000 mg/kg. The present findings suggest that MoP may serve as an effective and promising formulation for breast cancer drug delivery and therapy.

Breast cancer drug delivery by novel drug-loaded chitosan-coated magnetic nanoparticles

BackgroundBreast cancer is one of the most challenging cancers among women which is considered one of the most lethal cancers to this date. From the time that cancer has been discovered, finding the best therapeutic method is still an ongoing process. As a novel therapeutic method, nanomedicine has brought a vast number of materials that could versatilely be used as a drug carrier. The purpose of this study is to develop a novel black pomegranate peel extract loaded with chitosan-coated magnetic nanoparticles to treat breast cancer cells.ResultsThe morphology and size distribution of the nanoparticles studied by dynamic light scattering, atomic force microscopy, scanning, and transitional electron microscopy showed the spherical shape of the nanoparticles and their promising size range. Studies by Fourier transform infrared spectroscopy, X-ray diffraction, vibrating sample magnetometer, and zeta sizer confirmed the synthesis, substantial crystallinity, magnetic potential of the nanoparticles, and their satisfactory stability. The DPPH assay revealed that the obtained black pomegranate peel extract has 60% free radical scavenging activity. The cytotoxicity studies by MTT and LDH assay carried out on NIH/3T3, MBA-MB-231, and 4T1 cells confirmed that the magnetic nanoparticles had no significant cytotoxicity on the cells. However, the drug-loaded nanoparticles could significantly eradicate cancerous cells which had more efficiency comparing to free drug. Furthermore, free drug and drug-loaded nanoparticles had no toxic effect on normal cells.ConclusionOwing to the results achieved from this study, the novel drug-loaded nanoparticles are compatible to be used for breast cancer treatment and could potentially be used for further in vivo studies.

In vivo and In vitro Biocompatibility Study of Fe3O4@ZnO and Fe3O4@SiO2 as Photosensitizer for Targeted Breast Cancer Drug Delivery

The present study aimed to prepare Fe3O4 nanocarriers (NCs) by a thermal treatment method. After the Fe3O4 (Fe) NCs was prepared, zinc oxide and silica nanoparticles were added to it as Photosensitizer. The structure, morphology, and magnetic properties of Fe3O4@ZnO (Fe@Zn) and Fe3O4@SiO2 (Fe@Si) NCs were determined by XRD, FT-IR, FESEM, and VSM. Then, the loading and drug release of Fe, Fe@Zn, and Fe@Si NCs were investigated. The curcumin (CUR) release of Fe@Zn+CUR and Fe@Si+CUR increased from 30% and 26% at pH 7.4 to 53% and 57% at pH 5.5, respectively. The cytotoxicity of Fe@Zn and Fe@Si NCs were determined by MTT assay, hemolysis test, acute toxicity, and lethal dose test. The results showed that Fe@Zn and Fe@Si were appropriate for Photodynamic Therapy (PDT) and in the next step, the effect of Fe@Zn, Fe@Si, Fe@Zn+CUR, and Fe@Si+CUR NCs on MCF-7 cells under visible light were studied. Finally, the ranking of the destruction of cancerous cells of MCF-7 using NCs under visible light was: Fe@Zn+CUR>Fe@Zn>Fe@Si+CUR>Fe@Si.

Development of novel S PC-3 gefitinib lipid nanoparticles for effective drug delivery in breast cancer. Tissue distribution studies and cell cytotoxicity analysis

ObjectiveThe present work was aimed to develop gefitinib solid lipid nanoparticles (GFT-SLN) using novel lipids (Lipoid S PC-3) and to analyse its cell cytotoxicity and tissue distribution efficacy. MethodsGFT SLNs were prepared by a modified hot homogenization method using a variable concentration of lipid (Lipoid S PC-3) and poloxamer 407. GFT SLNs were characterised for physicochemical properties, in vitro drug release, cell cytotoxicity (MCF-7 cell lines), in vivo tissue distribution studies and stability analysis. ResultsThe mean particle size of SLNs was between 178 ± 10 to 348 ± 15 nm. A higher EE (>92%) and negative zeta potential (mV) was observed in all SLNs. FTIR and DSC data exhibit no possible interaction between the drug and excipients. PXRD reveal the amorphous nature of SLNs. SEM images show SLNs were of nanosize (<178.73 ± 10.66 nm) and spherical in shape. The in vitro release of SLNs showed an initial burst release (25%) within 2 h followed by a sustained release (>90%) during 72 h. Kinetic analysis of GFT SLNs fits best to the Higuchi model (R2 = 0.935). In vitro cytotoxicity of SLN demonstrated higher antitumour activity (cell viability >65%) in comparison to free drug (p < 0.05). In vivo tissue distribution studies show higher drug concentration in the liver (28,930 ± 91 ng), followed by kidneys (22,284 ± 1626 ng) and less in the brain (7042 ± 62 ng) (p < 0.05). GFT SLN was stable at 40 ± 2 °C/75 ± 5% RH and refrigerated temperature (4 ± 2 °C) during 3 months. ConclusionGFT SLNs developed using novel lipoid S PC-3 lipid offer higher antitumour efficacy and better drug distribution in tissues.